Pfizer Inc. (PFE)

36.80
0.16 0.45
NYSE : Health Technology
Prev Close 36.63
Open 36.67
Day Low/High 36.60 / 36.89
52 Wk Low/High 31.67 / 39.43
Volume 12.74M
Avg Volume 24.25M
Exchange NYSE
Shares Outstanding 5.95B
Market Cap 217.30B
EPS 3.60
P/E Ratio 10.38
Div & Yield 1.36 (3.56%)

Latest News

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

Pfizer Inc. (NYSE:PFE) announced today that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating...

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

The basic features of a prosperous corporate environment are all around us, but it's become difficult to stick to that narrative amid all the diversions, including from the President.

Global Stocks Tumble as China Fires Back in Trump Trade War

Global Stocks Tumble as China Fires Back in Trump Trade War

Global stocks tumbled, with markets in Asia losing all of their year-to-date gains, as China declared it's "not afraid" of an escalating trade war with the United States following President Trump's decision to target $50 billion in China-made goods.

Pfizer Reports Top-Line Results From A Study Of CHANTIX®/CHAMPIX® (varenicline) In Adolescent Smokers

Pfizer Reports Top-Line Results From A Study Of CHANTIX®/CHAMPIX® (varenicline) In Adolescent Smokers

Pfizer Inc. (NYSE:PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX ®/CHAMPIX ® (varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of...

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.

Dow Sinks 724 Points, or Nearly 3%, After Trump Announces China Trade Action

Dow Sinks 724 Points, or Nearly 3%, After Trump Announces China Trade Action

Stocks fall sharply on Thursday after Donald Trump announced a trade action against China that could be worth $60 billion.

Small-Cap Biotech and Tech Names Part of Our Latest 'Sweet 16' Stock Picks

Small-Cap Biotech and Tech Names Part of Our Latest 'Sweet 16' Stock Picks

Real Money stock picks from Tim Collins, Skip Raschke, Jim Collins and Bret Jensen.

Pfizer Invites Public To View And Listen To Webcast Of May 1 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of May 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

BioDuro Collaboration With Pfizer Inc. Leads To Creation Of A Shelf-Stable Fluorosulfation Reagent

BioDuro Collaboration With Pfizer Inc. Leads To Creation Of A Shelf-Stable Fluorosulfation Reagent

New reagent serves as a stable, solid alternative to toxic sulfuryl fluoride gas.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

The New #13 Most Shorted Dow Component: Pfizer

The New #13 Most Shorted Dow Component: Pfizer

The most recent short interest data has been released for the 02/26/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early...

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

TheStreet Quant Rating: B (Buy)